Precision oncology company Prelude Therapeutics Inc. (PRLD) surged to a dramatic close on Monday, ending the regular trading session at $3.98, up $2.39 or 150.31%, marking one of its most significant single-day gains in recent memory. The spike pushed the stock near the upper end of its 52-week range of $0.61 to $4.19, fueled by a trading volume of over 29 million shares, a staggering increase compared to its average daily volume of just 243,363 shares.
However, the momentum cooled in after-hours trading, with the stock dipping to $3.33, a decline of $0.65 or 16.33% from the closing price. Despite the pullback, PRLD remains well above its recent lows and continues to attract attention amid upcoming clinical data and conference presentations.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.